CDK4 inhibition and doxorubicin mediate breast cancer cell apoptosis through Smad3 and survivin

References

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277 - 300; http://dx.doi.org/10.3322/caac.20073; PMID: 20610543
   PubMed Web of Science ®Google Scholar
• Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CK, Musgrove EA, Sutherland RL. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993; 8:2127 - 33; PMID: 8336939
   PubMed Web of Science ®Google Scholar
• Keyomarsi K, Pardee AB. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci U S A 1993; 90:1112 - 6; http://dx.doi.org/10.1073/pnas.90.3.1112; PMID: 8430082
   PubMed Web of Science ®Google Scholar
• Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994; 54:1812 - 7; PMID: 8137296
   PubMed Web of Science ®Google Scholar
• Aaltonen K, Amini RM, Landberg G, Eerola H, Aittomäki K, Heikkilä P, Nevanlinna H, Blomqvist C. Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer. Breast Cancer Res Treat 2009; 113:75 - 82; http://dx.doi.org/10.1007/s10549-008-9908-5; PMID: 18240019
   PubMed Web of Science ®Google Scholar
• Hui R, Cornish AL, McClelland RA, Robertson JF, Blamey RW, Musgrove EA, Nicholson RI, Sutherland RL. Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clin Cancer Res 1996; 2:923 - 8; PMID: 9816251
   PubMed Web of Science ®Google Scholar
• Satyanarayana A, Kaldis P. Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene 2009; 28:2925 - 39; http://dx.doi.org/10.1038/onc.2009.170; PMID: 19561645
   PubMed Web of Science ®Google Scholar
• Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol 2009; 220:292 - 6; http://dx.doi.org/10.1002/jcp.21791; PMID: 19415697
   PubMed Web of Science ®Google Scholar
• Yu Q, Sicinska E, Geng Y, Ahnström M, Zagozdzon A, Kong Y, Gardner H, Kiyokawa H, Harris LN, Stål O, et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 2006; 9:23 - 32; http://dx.doi.org/10.1016/j.ccr.2005.12.012; PMID: 16413469
   PubMed Web of Science ®Google Scholar
• Landis MW, Pawlyk BS, Li T, Sicinski P, Hinds PW. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 2006; 9:13 - 22; http://dx.doi.org/10.1016/j.ccr.2005.12.019; PMID: 16413468
   PubMed Web of Science ®Google Scholar
• Matsuura I, Denissova NG, Wang G, He D, Long J, Liu F. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 2004; 430:226 - 31; http://dx.doi.org/10.1038/nature02650; PMID: 15241418
   PubMed Web of Science ®Google Scholar
• Tarasewicz E, Jeruss JS. Phospho-specific Smad3 signaling: impact on breast oncogenesis. Cell Cycle 2012; 11:2443 - 51; http://dx.doi.org/10.4161/cc.20546; PMID: 22659843
   PubMed Web of Science ®Google Scholar
• Yue J, Mulder KM. Transforming growth factor-beta signal transduction in epithelial cells. Pharmacol Ther 2001; 91:1 - 34; http://dx.doi.org/10.1016/S0163-7258(01)00143-7; PMID: 11707292
   PubMed Web of Science ®Google Scholar
• Burdette JE, Jeruss JS, Kurley SJ, Lee EJ, Woodruff TK. Activin A mediates growth inhibition and cell cycle arrest through Smads in human breast cancer cells. Cancer Res 2005; 65:7968 - 75; PMID: 16140969
   PubMed Web of Science ®Google Scholar
• Jeruss JS, Sturgis CD, Rademaker AW, Woodruff TK. Down-regulation of activin, activin receptors, and Smads in high-grade breast cancer. Cancer Res 2003; 63:3783 - 90; PMID: 12839974
   PubMed Web of Science ®Google Scholar
• Sundqvist A, Ten Dijke P, van Dam H. Key signaling nodes in mammary gland development and cancer: Smad signal integration in epithelial cell plasticity. Breast Cancer Res 2012; 14:204; http://dx.doi.org/10.1186/bcr3066; PMID: 22315972
   PubMed Web of Science ®Google Scholar
• Zelivianski S, Cooley A, Kall R, Jeruss JS. Cyclin-dependent kinase 4-mediated phosphorylation inhibits Smad3 activity in cyclin D-overexpressing breast cancer cells. Mol Cancer Res 2010; 8:1375 - 87; http://dx.doi.org/10.1158/1541-7786.MCR-09-0537; PMID: 20736297
   PubMed Web of Science ®Google Scholar
• Cooley A, Zelivianski S, Jeruss JS. Impact of cyclin E overexpression on Smad3 activity in breast cancer cell lines. Cell Cycle 2010; 9:4900 - 7; http://dx.doi.org/10.4161/cc.9.24.14158; PMID: 21150326
   PubMed Web of Science ®Google Scholar
• Dickson MA, Schwartz GK. Development of cell-cycle inhibitors for cancer therapy. Curr Oncol 2009; 16:36 - 43; PMID: 19370178
   PubMed Web of Science ®Google Scholar
• Bar-On O, Shapira M, Hershko DD. Differential effects of doxorubicin treatment on cell cycle arrest and Skp2 expression in breast cancer cells. Anticancer Drugs 2007; 18:1113 - 21; http://dx.doi.org/10.1097/CAD.0b013e3282ef4571; PMID: 17893511
   PubMed Web of Science ®Google Scholar
• Hortobágyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs 1997; 54:Suppl 4 1 - 7; PMID: 9361955
   PubMed Web of Science ®Google Scholar
• Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 24:1770 - 83; http://dx.doi.org/10.1200/JCO.2005.03.7689; PMID: 16603719
   PubMed Web of Science ®Google Scholar
• Reed JC, Bischoff JR. BIRinging chromosomes through cell division--and survivin’ the experience. Cell 2000; 102:545 - 8; http://dx.doi.org/10.1016/S0092-8674(00)00076-3; PMID: 11007472
   PubMed Web of Science ®Google Scholar
• Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3:917 - 21; http://dx.doi.org/10.1038/nm0897-917; PMID: 9256286
   PubMed Web of Science ®Google Scholar
• Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 1999; 341:452 - 3; http://dx.doi.org/10.1056/NEJM199908053410614; PMID: 10438269
   PubMed Web of Science ®Google Scholar
• Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, Dombret H, Reyes F, Diebold J, Gisselbrecht C, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000; 96:1921 - 5; PMID: 10961895
   PubMed Web of Science ®Google Scholar
• Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M, Takase K, Moriyama M, Kawano H, Hayashida M, et al. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 2000; 31:1080 - 5; http://dx.doi.org/10.1053/he.2000.6496; PMID: 10796883
   PubMed Web of Science ®Google Scholar
• Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998; 58:5071 - 4; PMID: 9823313
   PubMed Web of Science ®Google Scholar
• Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 2001; 92:271 - 8; http://dx.doi.org/10.1002/1097-0142(20010715)92:2<271::AID-CNCR1319>3.0.CO;2-0; PMID: 11466679
   PubMed Web of Science ®Google Scholar
• Xing N, Qian J, Bostwick D, Bergstralh E, Young CY. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Prostate 2001; 48:7 - 15; http://dx.doi.org/10.1002/pros.1076; PMID: 11391682
   PubMed Web of Science ®Google Scholar
• Ryan B, O’Donovan N, Browne B, O’Shea C, Crown J, Hill AD, McDermott E, O’Higgins N, Duffy MJ. Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer. Br J Cancer 2005; 92:120 - 4; http://dx.doi.org/10.1038/sj.bjc.6602314; PMID: 15611790
   PubMed Web of Science ®Google Scholar
• Yamashita S, Masuda Y, Kurizaki T, Haga Y, Murayama T, Ikei S, Kamei M, Takeno S, Kawahara K. Survivin expression predicts early recurrence in early-stage breast cancer. Anticancer Res 2007; 27:4C 2803 - 8; PMID: 17695451
   PubMedGoogle Scholar
• Hinnis AR, Luckett JC, Walker RA. Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Br J Cancer 2007; 96:639 - 45; http://dx.doi.org/10.1038/sj.bjc.6603616; PMID: 17285125
   PubMed Web of Science ®Google Scholar
• Yonesaka K, Tamura K, Kurata T, Satoh T, Ikeda M, Fukuoka M, Nakagawa K. Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin. Int J Cancer 2006; 118:812 - 20; http://dx.doi.org/10.1002/ijc.21350; PMID: 16108013
   PubMed Web of Science ®Google Scholar
• Olie RA, Simões-Wüst AP, Baumann B, Leech SH, Fabbro D, Stahel RA, Zangemeister-Wittke U. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 2000; 60:2805 - 9; PMID: 10850418
   PubMed Web of Science ®Google Scholar
• Yang J, Song K, Krebs TL, Jackson MW, Danielpour D. Rb/E2F4 and Smad2/3 link survivin to TGF-beta-induced apoptosis and tumor progression. Oncogene 2008; 27:5326 - 38; http://dx.doi.org/10.1038/onc.2008.165; PMID: 18504435
   PubMed Web of Science ®Google Scholar
• Jaffer S, Orta L, Sunkara S, Sabo E, Burstein DE. Immunohistochemical detection of antiapoptotic protein X-linked inhibitor of apoptosis in mammary carcinoma. Hum Pathol 2007; 38:864 - 70; http://dx.doi.org/10.1016/j.humpath.2006.11.016; PMID: 17350670
   PubMed Web of Science ®Google Scholar
• Bukholm IK, Berner JM, Nesland JM, Børresen-Dale AL. Expression of cyclin Ds in relation to p53 status in human breast carcinomas. Virchows Arch 1998; 433:223 - 8; http://dx.doi.org/10.1007/s004280050240; PMID: 9769125
   PubMed Web of Science ®Google Scholar
• Jeruss JS, Liu NX, Chung Y, Magrane G, Waldman F, Edgerton S, Yang X, Thor AD. Characterization and chromosomal instability of novel derived cell lines from a wt-erbB-2 transgenic mouse model. Carcinogenesis 2003; 24:659 - 64; http://dx.doi.org/10.1093/carcin/bgg001; PMID: 12727793
   PubMed Web of Science ®Google Scholar
• Li Y, Wang M, Carra C, Cucinotta FA. Modularized Smad-regulated TGFβ signaling pathway. Math Biosci 2012; 240:187 - 200; http://dx.doi.org/10.1016/j.mbs.2012.07.005; PMID: 22892478
   PubMed Web of Science ®Google Scholar
• Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009; 11:R77; http://dx.doi.org/10.1186/bcr2419; PMID: 19874578
   PubMed Web of Science ®Google Scholar
• Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Jiang A, Smith RA, Maira SM, et al. ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov 2011; 1:338 - 51; http://dx.doi.org/10.1158/2159-8290.CD-11-0101; PMID: 22049316
   PubMed Web of Science ®Google Scholar
• Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011; 11:558 - 72; http://dx.doi.org/10.1038/nrc3090; PMID: 21734724
   PubMed Web of Science ®Google Scholar
• Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, et al. Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18). AACR Meeting; 2014; San Diego Convention Center, San Diego, CA; 2014.
   Google Scholar
• Heldin CH, Moustakas A. Role of Smads in TGFβ signaling. Cell Tissue Res 2012; 347:21 - 36; http://dx.doi.org/10.1007/s00441-011-1190-x; PMID: 21643690
   PubMed Web of Science ®Google Scholar
• Shao J, Teraishi F, Katsuda K, Tanaka N, Fujiwara T. p53 inhibits adriamycin-induced down-regulation of cyclin D1 expression in human cancer cells. Biochem Biophys Res Commun 2002; 290:1101 - 7; http://dx.doi.org/10.1006/bbrc.2001.6314; PMID: 11798189
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay A, Wang L, Agyin J, Tang Y, Lin S, Yeh IT, De K, Sun LZ. Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS One 2010; 5:e10365; http://dx.doi.org/10.1371/journal.pone.0010365; PMID: 20442777
   PubMed Web of Science ®Google Scholar
• Ryan BM, Konecny GE, Kahlert S, Wang HJ, Untch M, Meng G, Pegram MD, Podratz KC, Crown J, Slamon DJ, et al. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol 2006; 17:597 - 604; http://dx.doi.org/10.1093/annonc/mdj121; PMID: 16403812
   PubMed Web of Science ®Google Scholar
• Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003; 22:8581 - 9; http://dx.doi.org/10.1038/sj.onc.1207113; PMID: 14634620
   PubMed Web of Science ®Google Scholar
• Fandy TE, Shankar S, Srivastava RK. Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells. Mol Cancer 2008; 7:60; http://dx.doi.org/10.1186/1476-4598-7-60; PMID: 18590557
   PubMed Web of Science ®Google Scholar
• Mansour A, Nabil M, Ali-Labib R, Said H, Annos F. Reciprocal expression of survivin and SMAC/DIABLO in primary breast cancer. Med Oncol 2012; 29:2535 - 42; http://dx.doi.org/10.1007/s12032-011-0129-0; PMID: 22161156
   PubMed Web of Science ®Google Scholar
• Flanagan L, Sebastià J, Tuffy LP, Spring A, Lichawska A, Devocelle M, Prehn JH, Rehm M. XIAP impairs Smac release from the mitochondria during apoptosis. Cell Death Dis 2010; 1:e49; http://dx.doi.org/10.1038/cddis.2010.26; PMID: 21364655
   PubMedGoogle Scholar
• Cao Z, Zhang R, Li J, Huang H, Zhang D, Zhang J, Gao J, Chen J, Huang C. X-linked inhibitor of apoptosis protein (XIAP) regulation of cyclin D1 protein expression and cancer cell anchorage-independent growth via its E3 ligase-mediated protein phosphatase 2A/c-Jun axis. J Biol Chem 2013; 288:20238 - 47; http://dx.doi.org/10.1074/jbc.M112.448365; PMID: 23720779
   PubMed Web of Science ®Google Scholar
• Che Y, Ye F, Xu R, Qing H, Wang X, Yin F, Cui M, Burstein D, Jiang B, Zhang DY. Co-expression of XIAP and cyclin D1 complex correlates with a poor prognosis in patients with hepatocellular carcinoma. Am J Pathol 2012; 180:1798 - 807; http://dx.doi.org/10.1016/j.ajpath.2012.01.016; PMID: 22429965
   PubMed Web of Science ®Google Scholar
• Song Z, Yao X, Wu M. Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem 2003; 278:23130 - 40; http://dx.doi.org/10.1074/jbc.M300957200; PMID: 12660240
   PubMed Web of Science ®Google Scholar
• Xiong J, Hu L, Li Y, Dou L, Cai P, Tang Z, Wang L. Effect of survivin regulation of transcription level by p21waf1 overexpression in HepG2 hepatocellular carcinoma cells. J Huazhong Univ Sci Technolog Med Sci 2008; 28:308 - 13; http://dx.doi.org/10.1007/s11596-008-0318-z; PMID: 18563330
   PubMed Web of Science ®Google Scholar
• Sun B, Wingate H, Swisher SG, Keyomarsi K, Hunt KK. Absence of pRb facilitates E2F1-induced apoptosis in breast cancer cells. Cell Cycle 2010; 9:1122 - 30; http://dx.doi.org/10.4161/cc.9.6.10990; PMID: 20237430
   PubMed Web of Science ®Google Scholar
• Appleyard MV, O’Neill MA, Murray KE, Paulin FE, Bray SE, Kernohan NM, Levison DA, Lane DP, Thompson AM. Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model. Int J Cancer 2009; 124:465 - 72; http://dx.doi.org/10.1002/ijc.23938; PMID: 19003963
   PubMed Web of Science ®Google Scholar
• Pardali K, Kurisaki A, Morén A, ten Dijke P, Kardassis D, Moustakas A. Role of Smad proteins and transcription factor Sp1 in p21(Waf1/Cip1) regulation by transforming growth factor-beta. J Biol Chem 2000; 275:29244 - 56; http://dx.doi.org/10.1074/jbc.M909467199; PMID: 10878024
   PubMed Web of Science ®Google Scholar